Acalabrutinib [1420477-60-6]

TargetMol Chemicals

Acalabrutinib [1420477-60-6]

9

1420477-60-6

Chemical

Research Use Only

Acalabrutinib

99.95%

C26H23N7O2

465.51

Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Brutons tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

3 years

CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12

-20°C

12352200